GlassScriptPhysician profile
Lauren E Hickman
NPI 1578241709
$1,455.24
in general payments reported to CMS, 2019-2025
23 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $221 · 2024: $823 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $247.25 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $179.67 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $167.11 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $132.07 | 2023-2025 | Shingrix, Arexvy |
| Lundbeck LLC | $107.80 | 2023-2025 | Rexulti, Vyepti |
| Lilly USA, LLC | $76.80 | 2024 | Mounjaro, Zepbound |
| Amgen INC. | $66.52 | 2024-2025 | Repatha, Otezla, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $63.72 | 2023-2025 | |
| Astellas Pharma US INC | $52.08 | 2024-2025 | Veozah |
| Shield Therapeutics INC | $43.98 | 2023-2024 | Accrufer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.49 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $32.77 | 2024-2025 | Airsupra |
| Azurity Pharmaceuticals, INC. | $32.50 | 2023-2025 | Azmiro, Edarbyclor |
| Pfizer INC. | $31.76 | 2024-2025 | |
| Exact Sciences Corporation | $29.56 | 2023 | Cologuard Collection Kit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $25.47 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth, Inogen One G3 Oxygen Concentrator |
| Philips North America LLC | $19.58 | 2024 | (Ck7) Extended Holter |
| Kyowa Kirin, INC. | $18.79 | 2024 | Crysvita |
| Tris Pharma INC | $18.56 | 2024 | Dyanavel Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.97 | 2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $17.62 | 2024 | Spravato |
| Viiv Healthcare Company | $17.28 | 2024 | Apretude |
| Dynavax Technologies Corporation | $14.89 | 2023 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Hickman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.